Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc.'s next confirmed earnings release is scheduled for February 4, 2027.

As of June 30, 2026, Thermo Fisher Scientific Inc. has 369.75M shares outstanding.

As of June 30, 2026, Thermo Fisher Scientific Inc. maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 80.57, indicating elevated leverage, while an interest coverage ratio of 7.56 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. posted a return on equity (ROE) of 13.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.16, useful for judging operating efficiency across full business cycles. The company generates approximately 324,463.21 in revenue per employee across its workforce of 125,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.90 indicates how many times Thermo Fisher Scientific Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. recorded 522.55M in income tax expense. That works out to an effective tax rate of 7.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.68B, leaving 6.10B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. generated 40.56B in revenue and converted that into 6.10B in net income, yielding earnings per share of 16.32. EBITDA reached 9.71B, while operating income came in at 7.42B.

As of June 30, 2026, Thermo Fisher Scientific Inc. holds 3.56B in cash and equivalents against 37.24B in total debt, resulting in a net debt position of 33.69B. Total book value stands at 46.11B, with working capital of 7.26B providing operational flexibility.

Thermo Fisher Scientific Inc. produced 7.89B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.48B in capital expenditures, free cash flow totaled 6.41B - equivalent to 17.12 per share.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. posted a gross margin of 40.80, reflecting its pricing power and cost economics. The operating margin of 18.29 and net profit margin of 15.04 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Thermo Fisher Scientific Inc. paid dividends of 1.55 per share. The dividend payout ratio of 9.44 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Thermo Fisher Scientific Inc.'s most recent stock split took place on June 6, 1996 with a 2:3 split ratio.